Comparison of clinical data between EXT1-positive and EXT1-negative cases in confirmed and suspected LMN
| Confirmed LMN | Suspected LMN | |||
| EXT1 positive (n=22) | EXT1 negative (n=8) | EXT1 positive (n=6) | EXT1 negative (n=31) | |
| Male, n (%) | 3.0 (13.6) | 0.0 (0.0) | 0.0 (0.0) | 9.0 (29.0) |
| Age (year) | 33.6±14.5 | 33.0±12.0 | 40.8±18.1* | 49.8±12.3 |
| Duration of lupus (month) | 1.0 (0.5–3.3)* | 60.0 (7.5–96.0) | — | — |
| MAP (mm Hg) | 103.5 (94.5–112.8)*† | 88.5 (81.8–104.3) | 94.0 (78.0–101.0) | 92.5 (84.3–107.0) |
| Erythema, n (%) | 15 (68.2) | 5 (62.5) | 0 (0.0) | 0 (0.0) |
| Joint pain, n (%) | 13 (59.0) | 5 (62.5) | 0 (0.0) | 5 (16.1) |
| Multiple serous cavity effusions, n (%) | 6 (27.2) | 4 (50.0) | 0 (0.0) | 6 (19.3) |
| Serum C3/C4 (mg/dL) | 6.7 (4.6–9.0)* | 4.7 (4.0–5.2) | 5.8 (4.8–7.4) | 4.7 (3.9–6.1) |
| Hb (g/L) | 111.0 (85.0–126.5) | 126.0 (120.0–126.0) | 123.0±12.2 | 118.5±15.8 |
| RBC (×1012/L) | 3.7±0.7 | 4.0±0.1 | 4.1±0.4 | 4.0±0.6 |
| WBC (×109/L) | 6.1±2.7 | 6.1±2.2 | 3.7±1.0* | 5.7±1.8 |
| PLT (×109/L) | 188.2±66.5* | 213.4±41.3 | 171.6±89.6* | 217.8±62.8 |
| ANA | 1:160 (1:200–1:80) | 1:160 (1:200–1:64) | 1:80 (1:80–1:40) | 1:40 (1:80–1:20) |
| dsDNA, n (%) | 10 (45.5) | 1 (12.5) | 0 (0.0) | 2 (6.5) |
| Anti-SM, n (%) | 9 (40.9) | 3 (37.5) | 0 (0.0) | 0 (0.0) |
| Anti-SSA, n (%) | 13 (59.1) | 3 (37.5) | 5 (83.3) | 16 (51.6) |
| Anti-SSB, n (%) | 8 (36.4) | 1 (12.5) | 1 (16.7) | 2 (6.5) |
| Duration of nephropathy (month) | 12.0 (1.8–42.0)* | 65.0 (12.0–115.0) | 2.5 (0.8–7.5) | 3.0 (1.0–24) |
| Haematuria (/HP) | 15.0 (6.5–41.5)* | 6.0 (2.0–19.7) | 7.0 (7.0–19.0) | 6.0 (3.0–11.5) |
| Proteinuria (g/24 hours) | 2.5 (1.2–5.2) | 1.2 (0.7–4.3) | 1.4 (0.7–4.0) | 2.2 (1.2–3.6) |
| Proteinuria ≥3.5/day, n (%) | 18 (81.8)*† | 3 (37.5) | 1 (16.7) | 8 (25.8) |
| Albumin (g/L) | 24.6±8.1 | 26.1±8.0 | 29.9±7.2 | 25.6±6.7 |
| SCR (µmol/L) | 68.1 (49.5–100.7)† | 55.0 (43.7–68.3) | 54.0 (42.5–61.3) | 54.7 (49.4–70.5) |
| eGFR (mL/min/1.73 m2) | 83.1±35.8*† | 108.8±31.4 | 104.3±12.7 | 91.5±37.0 |
Data were presented as n (%) or medians (IQR). Data with significant differences are highlighted in bold.
*EXT1-positive cases compared with EXT1-negative cases; p<0.05.
†EXT1-positive cases in confirmed LMN compared with EXT1-positive cases in suspected LMN; p<0.05.
anti-SSA, anti-Sjögren syndrome A antibody; anti-SSB, anti-Sjögren syndrome B antibody; dsDNA, double-stranded DNA; eGFR, estimated glomerular filtration rate; EXT1, exostosin 1; Hb, haemoglobin; LMN, lupus membranous nephropathy; MAP, mean arterial pressure; PLT, platelets; RBC, red blood cell; SCR, serum creatinine; SM, Smith antibody; WBC, white blood cell.